BlackRock, Inc. ownership in BM8 / BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

DE ˙ DB ˙ US09061G1013

45,69 € ↓ -1,20 (-2,56%)

2026-06-03
AKTIENPREIS

Security	DE:BM8 / BioMarin Pharmaceutical Inc.
Institution	BlackRock, Inc.
Latest Disclosed Ownership	17,560,751 shares
Ownership	9.10%

2026-01-21 - BlackRock, Inc. has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 17,560,751 shares of BioMarin Pharmaceutical Inc. (DE:BM8). This represents 9.1 percent ownership of the company. In their previous filing dated 2025-04-29 , BlackRock, Inc. had reported owning 20,620,179 shares, indicating a decrease of -14.84 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2026-01-21	2026-01-21	13G/A	20,620,179	17,560,751	-14.84	9.10	-15.74
2025-04-29	2025-04-29	13G/A	22,779,744	20,620,179	-9.48	10.80	-10.00
2024-07-08	2024-07-08	13G/A	14,740,836	22,779,744	54.53	12.00	53.85
2024-01-26	2024-01-26	13G/A	15,206,690	14,740,836	-3.06	7.80	-4.88
2023-02-03	2023-02-03	13G/A	14,021,292	15,206,690	8.45	8.20	7.89
2022-03-11	2022-03-11	13G/A	14,021,292	14,021,292	0.00	7.60	0.00
2022-02-08	2022-02-08	13G	14,766,892	14,021,292	-5.05	7.60	-6.17
2021-02-05	2021-02-05	13G/A	13,066,203	14,766,892	13.02	8.10	10.96
2020-02-10	2020-02-10	13G/A	13,588,187	13,066,203	-3.84	7.30	-3.95
2019-02-11	2019-02-11	13G/A	12,830,172	13,588,187	5.91	7.60	4.11
2018-02-08	2018-02-08	13G/A	10,610,120	12,830,172	20.92	7.30	17.74
2017-01-19	2017-01-19	13G/A	9,333,617	10,610,120	13.68	6.20	6.90
2016-02-10	2016-02-10	13G/A		9,333,617		5.80
2015-02-09	2015-02-09	13G/A		9,237,747		6.30
2014-02-11	2014-02-11	13G		8,488,405		6.00
2012-03-12	2012-03-12	13G/A		5,600,363		4.87
2012-02-09	2012-02-09	13G		6,461,126		5.63

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-13	2026-03-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	19,818,301	683,193	3.57	1,119,536	-1.55	0.0196
2026-02-12	2025-12-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	19,135,108	-2,910,942	-13.20	1,137,199	-4.76	0.0192
2025-11-12	2025-09-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	22,046,050	-1,955,625	-8.15	1,194,014	-9.50	0.0209
2025-08-12	2025-06-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	24,001,675	222,676	0.94	1,319,372	-21.51	0.0251
2025-05-02	2025-03-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	23,778,999	265,883	1.13	1,680,937	8.76	0.0353
2025-02-07	2024-12-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	23,513,116	889,613	3.93	1,545,517	-2.81	0.0313
2024-11-13	2024-09-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	22,623,503	-114,846	-0.51	1,590,206	-15.06	0.0334
2024-08-13	2024-06-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	22,738,349	8,259,559	57.05	1,872,048	48.04	0.0424
2024-05-10	2024-03-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	14,478,790	-202,854	-1.38	1,264,578	-10.67	0.0294
2024-02-13	2023-12-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	14,681,644	74,457	0.51	1,415,604	9.53	0.0361
2023-11-13	2023-09-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	14,607,187	591,722	4.22	1,292,444	6.39	0.0372
2023-08-11	2023-06-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	14,015,465	-623,111	-4.26	1,214,861	-14.65	0.0335
2023-05-12	2023-03-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	14,638,576	98,385	0.68	1,423,455	-5.40	0.0420
2023-02-13	2022-12-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	14,540,191	252,332	1.77	1,504,764	24.24	0.0471
2022-11-14	2022-09-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	14,287,859	-129,242	-0.90	1,211,184	1.38	0.0412
2022-08-12	2022-06-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	14,417,101	459,041	3.29	1,194,748	11.02	0.0383
2022-05-12	2022-03-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	13,958,060	56,879	0.41	1,076,167	-12.38	0.0290
2022-02-10	2021-12-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	13,901,181	-1,419,618	-9.27	1,228,172	3.72	0.0313
2021-11-09	2021-09-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	15,320,799	2,425,231	18.81	1,184,144	10.05	0.0332
2021-08-11	2021-06-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	12,895,568	-1,038,589	-7.45	1,076,006	2.27	0.0299
2021-05-07	2021-03-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	13,934,157	-780,003	-5.30	1,052,169	-18.45	0.0309
2021-02-05	2020-12-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	14,714,160	78,638	0.54	1,290,284	15.88	0.0412
2020-11-06	2020-09-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	14,635,522	-1,328,289	-8.32	1,113,472	-43.45	0.0411
2020-08-14	2020-06-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	15,963,811	1,368,101	9.37	1,968,977	59.65	0.0786
2020-05-01	2020-03-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	14,595,710	1,537,729	11.78	1,233,338	11.71	0.0603
2020-02-13	2019-12-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	13,057,981	157,268	1.22	1,104,054	26.97	0.0423
2019-11-08	2019-09-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	12,900,713	40,642	0.32	869,507	-21.06	0.0365
2019-08-22	2019-06-30	13F/A-1	BIOMARIN PHARMACEUTICAL	COM	09061G101	12,860,071	196,702	1.55	1,101,466	-2.08	0.0471
2019-08-13	2019-06-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	12,860,071	196,702		1,101,466
2019-05-09	2019-03-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	12,663,369	-915,193	-6.74	1,124,888	-2.71	0.0502
2019-02-08	2018-12-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	13,578,562	-544,751	-3.86	1,156,215	-15.58	0.0584
2018-11-09	2018-09-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	14,123,313	1,002,054	7.64	1,369,538	10.80	0.0593
2018-08-09	2018-06-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	13,121,259	323,227	2.53	1,236,023	19.13	0.0569
2018-05-09	2018-03-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	12,798,032	-21,712	-0.17	1,037,536	-9.24	0.0496
2018-02-09	2017-12-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	12,819,744	937,183	7.89	1,143,135	3.37	0.0544
2017-11-14	2017-09-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	11,882,561	481,601	4.22	1,105,909	6.81	0.0558
2017-08-10	2017-06-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	11,400,960	335,508	3.03	1,035,435	6.60	0.0549
2017-05-12	2017-03-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	11,065,452	10,909,162	6,980.08	971,324	7,402.31	0.0533
2017-02-10	2016-12-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	156,290	8,187	5.53	12,947	-5.52	0.0183
2016-11-08	2016-09-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	148,103	10,780	7.85	13,703	28.27	0.0197
2016-08-10	2016-06-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	137,323	-18,261	-11.74	10,683	-16.75	0.0161
2016-05-10	2016-03-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	155,584	7,276	4.91	12,833	-17.40	0.0206
2016-02-11	2015-12-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	148,308	48,959	49.28	15,537	48.49	0.0228
2015-11-13	2015-09-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	99,349	-44,498	-30.93	10,463	-46.82	0.0164
2015-08-07	2015-06-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	143,847	-129,588	-47.39	19,676	-42.26	0.0292
2015-05-13	2015-03-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	273,435	79,616	41.08	34,075	94.48	0.0471
2015-02-09	2014-12-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	193,819	-95,557	-33.02	17,521	-16.10	0.0251
2014-10-29	2014-09-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	289,376	-19,909	-6.44	20,882	8.53	0.0305
2014-08-06	2014-06-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	309,285	-97,498	-23.97	19,241	-30.66	0.0286
2014-05-02	2014-03-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	406,783	188,063	85.98	27,747	80.33	0.0448
2014-02-12	2013-12-31	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	218,720	136,828	167.08	15,387	160.31	0.0251
2013-11-12	2013-09-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	81,892	26,970	49.11	5,911	93.04	0.0111
2013-08-13	2013-06-30	13F	BIOMARIN PHARMACEUTICAL	COM	09061G101	54,922	54,922		3,062		0.0061

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.